Anti-centromere antibody
EstablishedAnti-centromere antibody is the classic marker for limited systemic sclerosis (CREST syndrome).
This antibody points to a more limited form of scleroderma, historically called CREST syndrome. Unlike the other scleroderma antibody, this one raises concern mainly about high blood pressure in the lung's blood vessels rather than lung scarring, so doctors watch for a different specific complication.
Anti-centromere antibodies (ACA) target kinetochore proteins and are the classic serologic marker for limited cutaneous systemic sclerosis (CREST syndrome), the counterpart to anti-Scl-70's association with diffuse disease.
Positive ACA supports a limited systemic sclerosis diagnosis, historically summarized as CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia), and carries a distinct risk profile emphasizing pulmonary arterial hypertension over the interstitial lung disease more typical of anti-Scl-70-positive disease.
Measured via indirect immunofluorescence (showing a characteristic speckled centromere staining pattern) or antigen-specific immunoassay, typically as part of the same ENA/scleroderma antibody panel as anti-Scl-70.
ACA positivity prompts specific surveillance for pulmonary arterial hypertension (via periodic echocardiography) rather than the interstitial lung disease surveillance emphasized in anti-Scl-70-positive patients, since these two antibody patterns predict genuinely different complication profiles requiring different monitoring approaches.
Predicts pulmonary arterial hypertension risk specifically, a genuinely different complication profile than anti-Scl-70-positive disease.
- General rheumatology reference literature on anti-centromere antibody in limited systemic sclerosis (CREST syndrome).